Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Por um escritor misterioso
Descrição
Full article: Patent landscape for discovery of promising
Diseases, Free Full-Text
US9701672B2 - Dihydropyridinone MGAT2 inhibitors for use in the
Targeting diacylglycerol acyltransferase 2 for the treatment of
NASH Target Development Service for DAG O-Acyltransferase (DGAT
New Drugs on the Block—Emerging Treatments for Nonalcoholic
Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the
Pharmacotherapies of NAFLD: updated opportunities based on
Therapeutic Approach to NAFLD-NASH
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
de
por adulto (o preço varia de acordo com o tamanho do grupo)
